Role of Bisphosphonates as Adjuvants of Surgery in Giant Cell Tumor of Spine
- PMID: 30619673
- PMCID: PMC6314347
- DOI: 10.14444/5087
Role of Bisphosphonates as Adjuvants of Surgery in Giant Cell Tumor of Spine
Abstract
Background: The role of bisphosphonates is well established in giant cell tumor of bone (GCTB) of extremities, but its role in spine GCTB is still not established. Our main purpose was to evaluate the role of bisphosphonates in spinal GCTB with the help of radiologic assessment.
Methods: A retrospective analysis of all spine GCTB patients who underwent an operation from July 2005 to January 2014 was done. Patients of spine GCTB in whom bisphosphonates were given constituted the study group. This group was compared to patients in whom bisphosphonates were not given. Preoperative and postoperative radiographs and CT scans were studied. A thorough evaluation of the presence of sclerosis was done on them. Bisphosphonates were considered to be effective if either sclerosis or new bone formation was present.
Results: A total of 13 cases of spine GCT underwent operation from July 2005 to January 2014. All patients of GCTB spine who underwent an operation after 2008 at our institute were given bisphosphonates postoperatively. Of 13 cases, bisphosphonates were given postoperatively in 6 patients: 5 patients were female and 1 patient was male. Of these 6 patients, 3 patients had sacrum GCTB and 1 patient each had T9, T11, and L5 vertebrae GCTB. Average follow-up period was 39.33 months (minimum follow-up was 18 months and maximum follow-up was 72 months). Postoperative sclerosis was present in all 6 patients. No recurrence of the tumor was present in the bisphosphonate group, but 2 patients had a recurrence in the group that did not receive bisphosphonates.
Conclusions: Bisphosphonates are effective and safe adjuvant therapy along with appropriate surgical intervention in spinal GCTBs and may have a role in decreasing the recurrence of this tumor.
Keywords: bisphosphonates; cryotherapy; metastasis; osteoclast; radiotherapy.
Conflict of interest statement
Disclosures and COI: The authors received no funding for this study and report no conflicts of interest.
Figures



Similar articles
-
Novel Strategy of Curettage and Adjuvant Microwave Therapy for the Treatment of Giant Cell Tumor of Bone in Extremities: A Preliminary Study.Orthop Surg. 2021 Feb;13(1):185-195. doi: 10.1111/os.12865. Epub 2021 Jan 13. Orthop Surg. 2021. PMID: 33442922 Free PMC article.
-
Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020929786. doi: 10.1177/2309499020929786. J Orthop Surg (Hong Kong). 2020. PMID: 32539628
-
Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.Oncologist. 2019 Jul;24(7):889-e421. doi: 10.1634/theoncologist.2019-0280. Epub 2019 Apr 30. Oncologist. 2019. PMID: 31040253 Free PMC article. Clinical Trial.
-
Multiprofessional Management of Giant Cell Tumors in the Cervical Spine: A Systematic Review.World Neurosurg. 2021 Jul;151:53-60. doi: 10.1016/j.wneu.2021.04.006. Epub 2021 Apr 12. World Neurosurg. 2021. PMID: 33857672
-
Comparative analysis of aggressiveness in giant cell tumor of bone between upper and lower extremities: A systematic review and meta-analysis.J Bone Oncol. 2025 Feb 8;51:100663. doi: 10.1016/j.jbo.2025.100663. eCollection 2025 Apr. J Bone Oncol. 2025. PMID: 40028631 Free PMC article. Review.
Cited by
-
Imaging Features of Aggressive Giant Cell Tumors of the Mobile Spine: Retrospective Analysis of 101 Patients From Single Center.Global Spine J. 2022 Sep;12(7):1449-1461. doi: 10.1177/2192568220982280. Epub 2021 Jan 27. Global Spine J. 2022. PMID: 33499650 Free PMC article.
-
Postoperative Fracture Risk in Giant Cell Tumor: A Case Report and Review of Literature.Cureus. 2023 Sep 29;15(9):e46192. doi: 10.7759/cureus.46192. eCollection 2023 Sep. Cureus. 2023. PMID: 37905245 Free PMC article.
-
Multimodal Management of Combined Posterior and Anterior Surgical Approach and Postoperative Pharmacological Therapy for Giant Cell Tumor of the Cervical Spine Encasing the Vertebral Artery: A Technical Case Report.Neurol Med Chir (Tokyo). 2022 Sep 15;62(9):438-443. doi: 10.2176/jns-nmc.2022-0158. Epub 2022 Aug 27. Neurol Med Chir (Tokyo). 2022. PMID: 36031352 Free PMC article.
-
Total resection of sacral giant cell tumor with en bloc resection, sacral nerve reconstruction, and custom 3D-printed implant: a case report with long-term follow-up.Int J Surg Case Rep. 2025 May;130:111293. doi: 10.1016/j.ijscr.2025.111293. Epub 2025 Apr 12. Int J Surg Case Rep. 2025. PMID: 40228346 Free PMC article.
-
Pathological predictors for curettage and cementation outcome in proximal tibial giant cell tumors.Bioinformation. 2025 Feb 28;21(2):190-195. doi: 10.6026/973206300210190. eCollection 2025. Bioinformation. 2025. PMID: 40322687 Free PMC article.
References
-
- Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am. 1982;64(5):755–761. - PubMed
-
- Settakorn J, Lekawanvijit S, Arpornchayanon O, et al. Spectrum of bone tumors in Chiang Mai University Hospital, Thailand according to WHO classification 2002: a study of 1,001 cases. J Med Assoc Thai. 2006;89(6):780–787. - PubMed
-
- Xing R, Yang J, Kong Q, Tu C, Zhou Y, Duan H. Giant cell tumour of bone in the appendicular skeleton: an analysis of 276 cases. Acta Orthop Belg. 2013;79(6):731–737. - PubMed
-
- Murphey MD, Andrews CL, Flemming DJ, Temple HT, Smith WS, Smirniotopoulos JG. From the archives of the AFIP: primary tumors of the spine: radiologic pathologic correlation. Radiographics. 1996;16(5):1131–1158. - PubMed
LinkOut - more resources
Full Text Sources